Viking CEO on ‘shocking’ market reaction to oral obesity data, preparing for Phase 3news2024-11-05T11:30:59+00:00November 5th, 2024|Endpoints News|
BioNTech says VEGF bispecific’s PD-L1 target, combo plans will be its edgenews2024-11-04T16:40:16+00:00November 4th, 2024|Endpoints News|
‘We play to win’: AstraZeneca details first results for oral GLP-1 and broader obesity ambitionsnews2024-11-04T15:55:13+00:00November 4th, 2024|Endpoints News|
MASH drug developers chart path forward as more patients use GLP-1snews2024-11-04T15:00:55+00:00November 4th, 2024|Endpoints News|
Viking’s oral weight loss drug shows promising Phase 1 datanews2024-11-04T02:18:03+00:00November 4th, 2024|Endpoints News|
CinRx touts positive data from two obesity drug candidatesnews2024-11-03T17:00:18+00:00November 3rd, 2024|Endpoints News|
Novo Nordisk claims late-stage MASH victory, continuing GLP-1’s expansionnews2024-11-01T15:28:32+00:00November 1st, 2024|Endpoints News|
Essa’s shares tank as it looks for options after abandoning prostate cancer drugnews2024-11-01T11:06:19+00:00November 1st, 2024|Endpoints News|
UCB’s anti-tau Alzheimer’s program fails Phase 2 primary endpoint, but highlights positive secondariesnews2024-10-31T19:24:55+00:00October 31st, 2024|Endpoints News|
Regeneron prepares to compete with Eylea biosimilar from Amgennews2024-10-31T18:46:31+00:00October 31st, 2024|Endpoints News|
